High <i>IL2RA</i>/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core‐binding factor-Reference-Cited by-同舟云学术

High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core‐binding factor

Published:2023-12-06 Issue:2 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Aoki Takahiro¹^ORCID,Shiba Norio²,Tsujimoto Shinichi²^ORCID,Yamato Genki³^ORCID,Hara Yusuke³,Kato Shota⁴,Yoshida Kenichi⁵,Ogawa Seishi⁶⁷⁸,Hayashi Yasuhide⁹,Iwamoto Shotaro¹⁰,Taki Tomohiko¹¹,Shimada Akira¹²,Iijima‐Yamashita Yuka¹³,Horibe Keizo¹³,Tawa Akio¹⁴,Taga Takashi¹⁵^ORCID,Adachi Souichi¹⁶,Tomizawa Daisuke¹⁷^ORCID

Affiliation:

1. Department of Pediatrics Graduate School of Medicine Chiba University Chiba Japan

2. Department of Pediatrics Yokohama City University Graduate School of Medicine Yokohama Japan

3. Department of Pediatrics Gunma University Graduate School of Medicine Maebashi Japan

4. Department of Pediatrics Graduate School of Medicine The University of Tokyo Tokyo Japan

5. Division of Cancer Evolution National Cancer Center Research Institute Tokyo Japan

6. Department of Pathology and Tumor Biology Graduate School of Medicine Kyoto University Kyoto Japan

7. Institute for the Advanced Study of Human Biology (WPI‐ASHBi) Kyoto University Kyoto Japan

8. Department of Medicine Center for Hematology and Regenerative Medicine Karolinska Institute Stockholm Sweden

9. Institute of Physiology and Medicine Jobu University Takasaki Japan

10. Department of Pediatrics Mie University Tsu Japan

11. Department of Medical Technology Kyorin University Faculty of Health Sciences Mitaka Japan

12. Department of Pediatrics Jichi Medical University Shimotsuke Japan

13. Clinical Research Center NHO Nagoya Medical Center Nagoya Japan

14. Higashiosaka Aramoto Heiwa Clinic Higashiosaka Japan

15. Department of Pediatrics Shiga University of Medical Science Shiga Japan

16. Department of Human Health Science Kyoto University Kyoto Japan

17. Division of Leukemia and Lymphoma Children's Cancer Center National Center for Child Health and Development Tokyo Japan

Abstract

AbstractCD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and an immunotherapy target in acute myeloid leukemia (AML). However, the clinical prevalence and significance of CD25 expression in pediatric AML are unknown. High IL2RA/CD25 expression in pediatric AML showed a stem cell‐like phenotype, and elevated CD25 expression was associated with lower overall survival (p < .001) and event‐free survival (p < .001) in the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 study. This finding was reproduced in AML without a core‐binding factor in the Children's Oncology Group study cohort. High CD25 expression has prognostic significance in pediatric AML.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30803

Reference21 articles.

1. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia

2. Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

3. CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo

4. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

5. Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis